Document is current

Article History

Received: 26 July 2023

Accepted: 7 March 2024

First Online: 19 March 2024

Declarations

:

: All methods in relation to this study were conducted in accordance with the ESOMAR guidelines and the Declaration of Helsinki (1964). Informed consent was obtained from all survey participants for anonymized data to be included in publications and were advised that any adverse events or product complaints raised would be reported to the relevant company. The study authors judged that no ethical review board permission was required for this study for the following reasons: (1) no patient-level data/ health data was collected, and no patient subjects were interrogated; (2) no subject-identifiable data were generated; (3) surveillance activities implied no risk or burden for any individuals; and (4) participants involved were physicians (doctors) in the capacity of a simple quantitative survey, where there was no impact on healthcare practice, standard of care or quality of care for patients in any capacity.

: Not applicable.

: KA declares receiving honoraria from Novo Nordisk for attending advisory boards and presenting at lectures. CB declares receiving honoraria from Novo Nordisk for presenting at lectures. CB is a board member of the Romanian Society of Diabetes, Nutrition, Metabolic Diseases; the Vice President of the Romanian Society of Hypertension; Honorary President of the Association for Education in Diabetes and Obesity; and Vice President of the Romanian Association for the Study of Obesity. AK declares receiving honoraria from Novo Nordisk for consulting services, attending advisory boards, presenting at lectures and a research grant, for different studies and paid to the Medical School of the National and Kapodistrian University of Athens, Athens, Greece. AK also declares receiving support from Novo Nordisk for attending meetings and/or travel. AK is the Chairman of the Metabolic Surgery Study Group; and the Vice President of the Hellenic Medical Association for Obesity.GS declares receiving honoraria from Novo Nordisk for attending advisory boards and presenting at lectures. GS also declares receiving support from Novo Nordisk for attending meetings and/or travel. GS is a board member of the Hungarian Society of Atherosclerosis; and the secretary general of the Hungarian Society of Obesity and Exercise Therapy. KHK declares receiving honoraria from Novo Nordisk for consulting services, attending advisory boards and presenting at lectures. KHK is a board member of the Czech Society of Diabetology and the Czech Society of Obesitology. AB and MB are employees of Novo Nordisk.